---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-123033"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T03:57:32.269865+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Innoviva appoints Derek Small to Board of Directors

## Summary
- Derek Small appointed effective April 29, 2024; independent director.
- Managing Director at Luson Bioventures; former CEO of Assembly Biosciences and Naurex.
- Receives initial RSU award of $125,000, prorated RSU of $18,750, and options for 833 shares.
- Annual cash retainer of $50,000; standard indemnification agreement with Innoviva.

## SEC filing metadata
- accession: 0001193125-24-123033
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000119312524123033/0001193125-24-123033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000119312524123033/d833151d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-123033
- JSON: https://secwatch.observer/filing/0001193125-24-123033.json
- Plain text: https://secwatch.observer/filing/0001193125-24-123033.txt

## Key facts
- Executive change
  Derek Small was appointed as Director at Innoviva, Inc..
  - Action: appointed
  - Role: Director
  source text: On and effective as of April 29, 2024 (the “Small Effective Date”), Innoviva, Inc. (the “Company”) appointed Derek Small, to its Board of Directors (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000119312524123033/0001193125-24-123033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.